TWTI

Overview

Highlights

News

Chart

Contacts

 

   
 
   
   
   
   
Approximate Financial Snapshot as of 3/11/08
Shares Outstanding 43.7M
52 Wk Hi/Lo 9.89/

4.83

Market Cap $310M
Recent Price $7.10

 

 

Join the SmallCapReview mailing list
Email:

 

Third Wave Technologies (TWTI)

Website: www.TWT.com

Develops and markets molecular diagnostic products


Overview

Third Wave Technologies (Nasdaq: TWTI) develops and markets molecular diagnostic products for various DNA and RNA analysis applications to clinical, research, and agricultural customers. 

 The company offers a number of products based on its Invader® chemistry for clinical testing. Third Wave offers in vitro diagnostic kits, and analyte specific, general purpose, and research use only reagents for nucleic acid analysis.

The company also develops various DNA and RNA analysis products for the research and agricultural biotechnology markets. Its customers include pharmaceutical and biotechnology companies, academic research centers, and health care providers. The company markets its products through an internal sales force, as well as collaborative relationships with pharmaceutical companies and research institutions in the United States and Europe.


TWTI Investor Highlights

  • Announced that the company achieved all primary clinical endpoints in the clinical trial for its human papillomavirus (HPV) tests. 
  • Reported revenue of $26.3 million for the year ended Dec. 31, 2007, an increase of 25% from 2006. The company reported research revenue of $4.6 million for 2007. Total revenues for the year ended Dec. 31, 2007, were $31.1 million.
  • Announced the appointment of Christopher Burton as the companys senior vice president of sales and marketing. Mr. Burton, 41, brings nearly 20 years of selling and marketing experience to his new role at Third Wave. He joins the company from GE Healthcare.
  • Recently announced that Inverness Medical Iberica, the Spanish affiliate of Inverness Medical Innovations, will distribute Third Waves HPV high-risk screening test in Spain and Portugal. Inverness Medical Iberica is a leader in the marketing of diagnostics to assist laboratory and health care professionals in both preventive and interventional medicine.

Recent News and Press Releases

Third Wave Completes FDA Submissions for Its Two HPV Products

Third Wave, DCL Medical Laboratories Form Strategic Partnership

Third Wave's InPlex(TM) CF Molecular Test Receives FDA Clearance

Third Wave's HPV Clinical Trial Achieves Primary Clinical Endpoints

Third Wave Reports Strong Full-Year 2007 Results, Continued Clinical Revenue Growth

Third Wave Responds to Court Ruling on Anti-Trust Claims in Digene Suit

Third Wave Announces First European HPV Distribution Partners

For the latest Quote and News on TWTI Click Here.


Three Month Chart




Contacts

Third Wave Technologies

502 South Rosa Road
Madison, WI 53719
Phone: 608-273-8933
Fax: 608-273-8618


SEC Filings

TWTI filings with the SEC can be found here. All Fillings are current and the Company is fully reporting.


Disclaimer

SmallCapReview.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. For continuing coverage of TWTI, please sign up for our free newsletter. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

Copyright SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act  of 1933, Section 17(b), SmallCapReview.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview.com web site. SmallCapReview.com has not been compensated for its efforts in presenting the Third Wave Technologies profile on its website and distributing it to its database of subscribers. SmallCapReview.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.